Does ROSUVASTATIN Cause Hepatocellular injury? 232 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 232 reports of Hepatocellular injury have been filed in association with ROSUVASTATIN (Rosuvastatin Calcium). This represents 0.6% of all adverse event reports for ROSUVASTATIN.
232
Reports of Hepatocellular injury with ROSUVASTATIN
0.6%
of all ROSUVASTATIN reports
5
Deaths
162
Hospitalizations
How Dangerous Is Hepatocellular injury From ROSUVASTATIN?
Of the 232 reports, 5 (2.2%) resulted in death, 162 (69.8%) required hospitalization, and 24 (10.3%) were considered life-threatening.
Is Hepatocellular injury Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ROSUVASTATIN. However, 232 reports have been filed with the FAERS database.
What Other Side Effects Does ROSUVASTATIN Cause?
Myalgia (3,958)
Dyspnoea (2,832)
Pain (2,758)
Drug ineffective (2,347)
Fatigue (2,208)
Rhabdomyolysis (2,173)
Arthralgia (1,879)
Asthma (1,843)
Muscle spasms (1,843)
Pain in extremity (1,686)
What Other Drugs Cause Hepatocellular injury?
ACETAMINOPHEN (1,761)
METHOTREXATE (683)
ATORVASTATIN (610)
SULFAMETHOXAZOLE\TRIMETHOPRIM (415)
ENOXAPARIN (365)
TRAMADOL (349)
AMOXICILLIN (347)
ESOMEPRAZOLE (341)
PANTOPRAZOLE (340)
VINCRISTINE (306)
Which ROSUVASTATIN Alternatives Have Lower Hepatocellular injury Risk?
ROSUVASTATIN vs ROSUVASTATIN\ROSUVASTATIN
ROSUVASTATIN vs ROTIGOTINE
ROSUVASTATIN vs ROXADUSTAT
ROSUVASTATIN vs ROXICODONE
ROSUVASTATIN vs ROXITHROMYCIN